Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ETN001
MIFTS: 61

Eating Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Eating Disorder

About this section

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 15
Eating Disorders 37 55 43 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:8670
ICD10 33 F50 F50.9
ICD9CM 35 307.50
NCIt 50 C89332
KEGG 37 H01703
UMLS 73 C0013473
Sources

Summaries for Eating Disorder

About this section
MedlinePlus : 43 Eating disorders are serious behavior problems. They can include severe overeating or not consuming enough food to stay healthy. They also involve extreme concern about your shape or weight. Types of eating disorders include Anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat Bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives Binge-eating, which is out-of-control eating Women are more likely than men to have eating disorders. They usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. Eating disorders can lead to heart and kidney problems and even death. Getting help early is important. Treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. NIH: National Institute of Mental Health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to borderline personality disorder and bulimia nervosa, and has symptoms including decrease in appetite, adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Adipocytokine signaling pathway and cAMP signaling pathway. The drugs Dopamine and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia : 76 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Sources

Related Diseases for Eating Disorder

About this section

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 borderline personality disorder 31.7 BDNF COMT HTR2C SLC6A4
2 bulimia nervosa 31.7 BDNF CCK COMT GHRL LEP NPY
3 gastroparesis 31.5 CCK DRD2 GHRL
4 alexithymia 31.0 COMT DRD2 SLC6A4
5 dyspepsia 30.5 CCK GHRL SLC6A4
6 social phobia 30.3 CCK DRD2 SLC6A4
7 chronic pain 30.3 CNR1 COMT
8 pathological gambling 30.3 DRD2 SLC6A3 SLC6A4
9 depression 30.1 BDNF CRH HTR2C SLC6A4
10 generalized anxiety disorder 30.1 BDNF DRD2 SLC6A4
11 alcohol abuse 30.0 BDNF CNR1 DRD2 SLC6A4
12 celiac disease 1 29.8 CCK GHRL PYY
13 amenorrhea 29.8 CRH LEP POMC
14 fibromyalgia 29.8 COMT CRH NPY SLC6A4
15 withdrawal disorder 29.2 CNR1 CRH POMC
16 narcolepsy 29.2 COMT DRD2 GHRL LEP SLC6A3
17 personality disorder 29.2 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
18 restless legs syndrome 29.1 DRD2 POMC SLC6A3
19 autism 29.1 BDNF COMT DRD2 SLC6A3 SLC6A4
20 obsessive-compulsive disorder 28.9 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
21 substance abuse 28.8 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
22 attention deficit-hyperactivity disorder 28.3 BDNF COMT DRD2 HTR2C NPY SLC6A3
23 substance dependence 28.3 BDNF CNR1 DRD2 POMC SLC6A3 SLC6A4
24 anxiety 28.3 BDNF CCK CNR1 COMT CRH HTR2C
25 sleep apnea 28.3 ADIPOQ GHRL LEP LEPR
26 bipolar disorder 27.8 BDNF COMT CRH DRD2 HTR2C SLC6A3
27 panic disorder 27.5 BDNF CCK COMT CRH HTR2C POMC
28 morbid obesity 27.2 ADIPOQ CCK GHRL LEP LEPR MC4R
29 mood disorder 27.0 BDNF COMT CRH DRD2 HTR2C NPY
30 schizophrenia 26.6 BDNF CCK CNR1 COMT DRD2 HTR2C
31 major depressive disorder 26.2 BDNF COMT CRH DRD2 HTR2C NPY
32 anorexia nervosa 26.1 ADIPOQ BDNF CCK COMT CRH GHRL
33 disease of mental health 25.4 BDNF CCK CNR1 COMT CRH DRD2
34 body mass index quantitative trait locus 11 22.7 ADIPOQ CCK CNR1 CRH DRD2 GHRL
35 rumination disorder 11.5
36 autism spectrum disorder 10.9
37 extrapontine myelinolysis 10.9
38 wernicke-korsakoff syndrome 10.7
39 stereotypic movement disorder 10.7 CCK NPY
40 cannabis abuse 10.7 BDNF CNR1
41 paranoid schizophrenia 10.6 BDNF COMT SLC6A4
42 schizophreniform disorder 10.6 COMT DRD2
43 osteoporosis, juvenile 10.6
44 pica disease 10.6
45 telogen effluvium 10.6
46 central pontine myelinolysis 10.6
47 brittle diabetes 10.6
48 mbd25-related intellectual disability 10.6
49 cerebral beriberi 10.6
50 korsakoff's amnesic syndrome 10.6

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):


Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder
Sources

Symptoms & Phenotypes for Eating Disorder

About this section

UMLS symptoms related to Eating Disorder:


decrease in appetite, adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 SLC6A4 PYY SLC6A3 CRH CCK ADIPOQ
2 homeostasis/metabolism MP:0005376 10.47 SLC6A4 PYY SLC6A3 COMT CRH CCK
3 growth/size/body region MP:0005378 10.4 SLC6A3 POMC SLC6A4 PYY BDNF ADIPOQ
4 adipose tissue MP:0005375 10.37 PYY CRH ADIPOQ CNR1 LEP GHRL
5 endocrine/exocrine gland MP:0005379 10.35 SLC6A4 SLC6A3 BDNF COMT CCK ADIPOQ
6 nervous system MP:0003631 10.31 SLC6A4 PYY SLC6A3 COMT CCK CNR1
7 integument MP:0010771 10.25 SLC6A3 SLC6A4 BDNF ADIPOQ CNR1 DRD2
8 immune system MP:0005387 10.22 SLC6A3 POMC COMT ADIPOQ DRD2 CRH
9 hematopoietic system MP:0005397 10.2 SLC6A3 POMC COMT ADIPOQ DRD2 CRH
10 digestive/alimentary MP:0005381 10.12 BDNF CNR1 DRD2 GHRL NPY LEPR
11 normal MP:0002873 10.11 SLC6A3 SLC6A4 PYY BDNF CNR1 DRD2
12 liver/biliary system MP:0005370 10.1 POMC ADIPOQ DRD2 LEP CRH NPY
13 muscle MP:0005369 10.02 SLC6A3 SLC6A4 ADIPOQ DRD2 HTR2C LEPR
14 no phenotypic analysis MP:0003012 10.01 POMC BDNF CCK CNR1 DRD2 CRH
15 renal/urinary system MP:0005367 9.97 POMC COMT CCK ADIPOQ DRD2 LEP
16 neoplasm MP:0002006 9.93 POMC ADIPOQ DRD2 LEPR LEP MC4R
17 reproductive system MP:0005389 9.86 SLC6A3 COMT BDNF CNR1 DRD2 LEPR
18 respiratory system MP:0005388 9.76 COMT BDNF ADIPOQ DRD2 CRH LEPR
19 skeleton MP:0005390 9.65 SLC6A3 PYY ADIPOQ CNR1 DRD2 LEP
20 taste/olfaction MP:0005394 8.92 SLC6A3 BDNF CNR1 DRD2
Sources

Drugs & Therapeutics for Eating Disorder

About this section

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Topiramate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
3
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
4
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
5
Zinc Approved, Investigational Phase 4,Phase 1,Phase 2 7440-66-6 23994
6
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
7
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
8
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
9
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
10
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
11
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
12
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
13
Baclofen Approved Phase 4,Not Applicable 1134-47-0 2284
14
Phentermine Approved, Illicit Phase 4,Phase 2,Phase 1 122-09-8 4771
15
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
16
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 5826 3007
17
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
18
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
19
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
20
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
21
Cyproheptadine Approved Phase 4 129-03-3 2913
22
Histamine Approved, Investigational Phase 4,Not Applicable 75614-87-8, 51-45-6 774
23
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27 Raclopride Investigational Phase 4 84225-95-6
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
29 Micronutrients Phase 4,Phase 1,Phase 2
30 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
34 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
35 Narcotics Phase 4,Phase 2,Phase 3,Not Applicable
36 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
40 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Trace Elements Phase 4,Phase 1,Phase 2
43 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Vitamin B Complex Phase 4
50 Vitamins Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 627)
# Name Status NCT ID Phase Drugs
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 Folic Acid Supplementation in Eating Disorder Completed NCT01493674 Phase 4
3 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
4 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
5 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
6 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
7 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
8 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
9 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
10 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
11 The Effects of Body Contouring: Abdominoplasty and Liposuction Completed NCT02151799 Phase 4
12 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
13 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
14 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
15 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
16 Baclofen for Rumination Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
17 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
18 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
19 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
20 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
21 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
22 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4 Orlistat
23 Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Completed NCT01341236 Phase 4
24 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
25 Lifestyle Modification and Liraglutide Active, not recruiting NCT02911818 Phase 4 Liraglutide 3.0mg;Placebo Oral Tablet;Phentermine 15 MG
26 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Not yet recruiting NCT02568007 Phase 4 Cyproheptadine
27 Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children Not yet recruiting NCT03098810 Phase 4 Zinc sulphate
28 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
29 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
30 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
31 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
32 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
33 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
34 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
35 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
36 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3 Lamotrigine;placebo
37 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
38 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
39 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
40 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
41 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
42 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3 Zonegran;sugar pill
43 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
44 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
45 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3 topiramate
46 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
47 A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
48 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
49 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
50 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Eating Disorder

About this section
Sources

Anatomical Context for Eating Disorder

About this section

MalaCards organs/tissues related to Eating Disorder:

41
Bone, Brain, Heart, Testes, Kidney, Liver, Breast
Sources

Publications for Eating Disorder

About this section

Articles related to Eating Disorder:

(show top 50) (show all 1087)
# Title Authors Year
1
Food specific inhibitory control under negative mood in binge-eating disorder: Evidence from a multimethod approach. ( 29341203 )
2018
2
Implicit and explicit changes in body satisfaction evoked by body size illusions: Implications for eating disorder vulnerability in women. ( 29928005 )
2018
3
Beyond the tip of the iceberg: Adolescent weight development of women and men with features of binge eating disorder. ( 29933124 )
2018
4
Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain. ( 29655552 )
2018
5
Do eating disorder voice characteristics predict treatment outcomes in anorexia nervosa? A pilot study. ( 29882721 )
2018
6
An examination of eating disorder education and experience in a 1-month adolescent medicine rotation: what is sufficient to foster adequate self-efficacy? ( 29953405 )
2018
7
Stress-induced eating in women with binge-eating disorder and obesity. ( 27836626 )
2018
8
The Contribution of Social Media to Body Dissatisfaction, Eating Disorder Symptoms, and Anabolic Steroid Use Among Sexual Minority Men. ( 29363993 )
2018
9
Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. ( 29942715 )
2018
10
Eating Disorder Symptomatology and Identity Formation in Adolescence: A Cross-Lagged Longitudinal Approach. ( 29915548 )
2018
11
Improving access to eating disorder services. ( 29378681 )
2018
12
Media Smart-Targeted: Diagnostic outcomes from a two-country pragmatic online eating disorder risk reduction trial for young adults. ( 29377203 )
2018
13
The relationship between trauma and weight status among adolescents in eating disorder treatment. ( 29969660 )
2018
14
Cyber Victimization Is Associated With Eating Disorder Psychopathology in Adolescents. ( 29962992 )
2018
15
Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. ( 29407005 )
2018
16
Subjective and Objective: Alexithymia and Social Cognition in Eating Disorders. ( 29916406 )
2018
17
A content analysis of an online pro-eating disorder community on Reddit. ( 29414146 )
2018
18
Network analysis: An innovative framework for understanding eating disorder psychopathology. ( 29451959 )
2018
19
A Screening Tool for Detecting Eating Disorder Risk and Diagnostic Symptoms among College-Age Women. ( 29979922 )
2018
20
Binge eating disorder and depressive symptoms among females of child-bearing age: the Korea Nurses' Health Study. ( 29343226 )
2018
21
Perfectionism is associated with higher eating disorder symptoms and lower remission in children and adolescents diagnosed with eating disorders. ( 29803120 )
2018
22
Ghrelin concentration as an indicator of eating-disorder risk in obese women. ( 29395813 )
2018
23
Meta-analysis of the effects of cognitive-behavioral therapy on the core eating disorder maintaining mechanisms: implications for mechanisms of therapeutic change. ( 29378481 )
2018
24
The relationship between body mass index, binge eating disorder and suicidality. ( 29907143 )
2018
25
Acute Massive Gastric Dilatation in a Patient with an Eating Disorder. ( 29491312 )
2018
26
Fasting and postprandial soluble epoxide hydrolase-associated eicosanoids of remitted patients with eating disorder. ( 29876402 )
2018
27
How Does Food Taste in Anorexia and Bulimia Nervosa? A Protocol for a Quasi-Experimental, Cross-Sectional Design to Investigate Taste Aversion or Increased Hedonic Valence of Food in Eating Disorders. ( 29593595 )
2018
28
Patient Experiences Using a Self-Monitoring App in Eating Disorder Treatment: Qualitative Study. ( 29934285 )
2018
29
Childhood body mass index and development of eating disorder traits across adolescence. ( 29927002 )
2018
30
Patients with Binge Eating Disorder and Obesity have qualitatively different interpersonal characteristics: Results from an Interpersonal Circumplex study. ( 29960139 )
2018
31
Associations among eating disorder behaviors and eating disorder quality of life in adult women with anorexia nervosa. ( 29886272 )
2018
32
Feeling fat in eating disorders: Testing the unique relationships between feeling fat and measures of disordered eating in anorexia nervosa and bulimia nervosa. ( 29653375 )
2018
33
Eating disorder or oesophageal achalasia during adolescence: diagnostic difficulties. ( 29774515 )
2018
34
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
35
The impact of self-imagery on aspects of the self-concept in individuals with high levels of eating disorder cognitions. ( 29859373 )
2018
36
Economic evaluation of cognitive behavioral therapy and Internet-based guided self-help for binge-eating disorder. ( 29345848 )
2018
37
Subjective incompetence as a predictor of treatment outcomes in eating disorder outpatients. ( 29870956 )
2018
38
Neuroimaging in bulimia nervosa and binge eating disorder: a systematic review. ( 29468065 )
2018
39
Validation of the Spanish Version of the Yale Food Addiction Scale 2.0 (YFAS 2.0) and Clinical Correlates in a Sample of Eating Disorder, Gambling Disorder, and Healthy Control Participants. ( 29887808 )
2018
40
Hypomagnesemia in a Patient With an Eating Disorder. ( 29389386 )
2018
41
Implementation of enhanced cognitive behaviour therapy (CBT-E) for adults with anorexia nervosa in an outpatient eating-disorder unit at a public hospital. ( 29854400 )
2018
42
Affective predictors of the severity and change in eating psychopathology in residential eating disorder treatment: The role of social anxiety. ( 29384466 )
2018
43
Effect of dopamine receptor D4 (DRD4) haplotypes on general psychopathology in patients with eating disorders. ( 29455021 )
2018
44
Body composition and physical fitness in women with bulimia nervosa or binge-eating disorder. ( 29473191 )
2018
45
Increased prevalence of eating disorders as a biopsychosocial implication of food allergy. ( 29944672 )
2018
46
Beyond the Binary: Differences in Eating Disorder Prevalence by Gender Identity in a Transgender Sample. ( 29359198 )
2018
47
A narrative review of binge eating disorder in adolescence: prevalence, impact, and psychological treatment strategies. ( 29379325 )
2018
48
Inducing negative affect using film clips with general and eating disorder-related content. ( 29423687 )
2018
49
Eating disorders in children: is avoidant-restrictive food intake disorder a feeding disorder or an eating disorder and what are the implications for treatment? ( 29399331 )
2018
50
A cross-sectional model of eating disorders in Argentinean overweight and obese children. ( 27678154 )
2018
Sources

Variations for Eating Disorder

About this section
Sources

Expression for Eating Disorder

About this section
Search GEO for disease gene expression data for Eating Disorder.
Sources

Pathways for Eating Disorder

About this section

Pathways related to Eating Disorder according to KEGG:

37
# Name Kegg Source Accession
1 Adipocytokine signaling pathway hsa04920
2 cAMP signaling pathway hsa04024

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 13.88 CCK CNR1 CRH DRD2 GHRL HTR2C
2
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.34 ADIPOQ BDNF CNR1 DRD2 LEP LEPR
3
G-Beta Gamma Signaling 64
Show member pathways
 12.71 BDNF CNR1 CRH DRD2 HTR2C POMC
4
Peptide ligand-binding receptors 66
Show member pathways
 12.67 CCK CNR1 CRH DRD2 GHRL HTR2C
5
Neuroscience 4
12.36 CNR1 COMT NPY POMC
6
cAMP signaling pathway 37
Show member pathways
 12.04 BDNF DRD2 GHRL NPY
8
Amphetamine addiction 37
Show member pathways
 11.75 BDNF DRD2 SLC6A3
9
Adipocytokine signaling pathway 37
11.19 ADIPOQ LEP LEPR NPY POMC
10
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 10.97 LEP LEPR POMC
11
Transcription factor regulation in adipogenesis 1
10.89 ADIPOQ LEP
12
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 10.85 COMT SLC6A3 SLC6A4
13
Syndecan-3-mediated signaling events 1
10.73 MC4R POMC
14
Cell-type Dependent Selectivity of CCK2R Signaling 1
10.59 CCK CNR1
15
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10.3 CRH POMC
Sources

GO Terms for Eating Disorder

About this section

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 ADIPOQ BDNF CCK CRH GHRL LEP
2 dendrite GO:0030425 9.65 BDNF CCK COMT DRD2 HTR2C
3 extracellular region GO:0005576 9.65 ADIPOQ BDNF CCK CRH GHRL LEP
4 perikaryon GO:0043204 9.5 CCK CRH DRD2
5 axon GO:0030424 9.17 BDNF CCK CNR1 COMT DRD2 GHRL

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.98 BDNF DRD2 NPY POMC PYY
2 response to hypoxia GO:0001666 9.92 ADIPOQ DRD2 LEP SLC6A4
3 neuropeptide signaling pathway GO:0007218 9.88 NPY POMC PYY
4 female pregnancy GO:0007565 9.87 COMT CRH LEP
5 locomotory behavior GO:0007626 9.87 DRD2 HTR2C SLC6A3
6 response to drug GO:0042493 9.87 ADIPOQ COMT CRH DRD2 HTR2C SLC6A3
7 circadian rhythm GO:0007623 9.86 ADIPOQ LEP SLC6A4
8 memory GO:0007613 9.86 BDNF CNR1 SLC6A4
9 regulation of signaling receptor activity GO:0010469 9.86 ADIPOQ BDNF CCK GHRL LEP NPY
10 regulation of blood pressure GO:0008217 9.84 LEP NPY POMC
11 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.83 CNR1 DRD2 MC4R
12 response to estrogen GO:0043627 9.83 COMT CRH GHRL
13 glucose metabolic process GO:0006006 9.82 ADIPOQ GHRL LEP
14 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.82 CNR1 HTR2C NPY
15 response to nutrient levels GO:0031667 9.81 ADIPOQ GHRL LEP
16 response to nutrient GO:0007584 9.81 ADIPOQ CNR1 LEP SLC6A4
17 glucose homeostasis GO:0042593 9.8 ADIPOQ CNR1 LEP LEPR POMC
18 response to nicotine GO:0035094 9.77 CNR1 DRD2 SLC6A3
19 positive regulation of multicellular organism growth GO:0040018 9.75 DRD2 GHRL SLC6A3
20 response to cocaine GO:0042220 9.73 CNR1 CRH DRD2 SLC6A3
21 response to pain GO:0048265 9.72 COMT CRH
22 synaptic transmission, dopaminergic GO:0001963 9.72 CRH DRD2
23 negative regulation of blood pressure GO:0045776 9.72 ADIPOQ CNR1 DRD2
24 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
25 central nervous system neuron development GO:0021954 9.71 LEP NPY
26 dopamine metabolic process GO:0042417 9.71 COMT DRD2
27 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
28 negative regulation of gluconeogenesis GO:0045721 9.7 ADIPOQ LEPR
29 regulation of synaptic transmission, GABAergic GO:0032228 9.7 CNR1 DRD2
30 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
31 sexual reproduction GO:0019953 9.68 LEP LEPR
32 negative regulation of appetite GO:0032099 9.68 CCK LEP
33 leptin-mediated signaling pathway GO:0033210 9.68 LEP LEPR
34 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
35 positive regulation of growth hormone secretion GO:0060124 9.67 DRD2 GHRL
36 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
37 energy reserve metabolic process GO:0006112 9.67 LEP LEPR MC4R
38 dopamine catabolic process GO:0042420 9.66 COMT SLC6A3
39 regulation of feeding behavior GO:0060259 9.65 CNR1 LEPR MC4R
40 regulation of bone remodeling GO:0046850 9.64 LEP LEPR
41 dopamine uptake involved in synaptic transmission GO:0051583 9.63 SLC6A3 SLC6A4
42 adult feeding behavior GO:0008343 9.63 GHRL LEP NPY
43 response to ethanol GO:0045471 9.63 ADIPOQ CNR1 CRH DRD2 LEP SLC6A3
44 positive regulation of corticotropin secretion GO:0051461 9.62 CRH GHRL
45 positive regulation of appetite GO:0032100 9.61 GHRL NPY
46 regulation of metabolic process GO:0019222 9.61 LEP MC4R
47 positive regulation of cortisol secretion GO:0051464 9.6 CRH GHRL
48 negative regulation of dopamine secretion GO:0033602 9.57 CNR1 DRD2
49 negative regulation of glucagon secretion GO:0070093 9.56 CRH LEP
50 bone growth GO:0098868 9.54 LEP LEPR

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.78 CNR1 DRD2 HTR2C MC4R
2 signaling receptor binding GO:0005102 9.7 ADIPOQ CRH DRD2 LEP NPY POMC
3 drug binding GO:0008144 9.62 CNR1 DRD2 HTR2C SLC6A3
4 G-protein coupled receptor binding GO:0001664 9.56 GHRL NPY POMC PYY
5 neurotransmitter:sodium symporter activity GO:0005328 9.46 SLC6A3 SLC6A4
6 dopamine binding GO:0035240 9.43 DRD2 SLC6A3
7 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
9 neuropeptide hormone activity GO:0005184 9.35 CCK CRH NPY POMC PYY
10 hormone activity GO:0005179 9.23 ADIPOQ CCK CRH GHRL LEP NPY
Sources

Sources for Eating Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....